-
公开(公告)号:US10213426B2
公开(公告)日:2019-02-26
申请号:US15455684
申请日:2017-03-10
申请人: Buck Institute for Research on Aging , Unity Biotechnology, Inc. , Mayo Foundation for Medical Education and Research
发明人: Remi-Martin Laberge , Judith Campisi , Albert Davalos , Marco Demaria , Nathaniel David , Yi Zhu , James L. Kirkland , Tamar Tchkonia
IPC分类号: G01N1/00 , C12Q1/00 , A61K31/496 , A61K31/428 , A61K31/495 , A61K31/5377 , A61K31/404 , A61K31/4375 , A61K45/06 , A61K31/4178 , A61K31/728 , C12N5/00 , A61K47/36 , A61K9/00
摘要: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
-
公开(公告)号:US10010546B2
公开(公告)日:2018-07-03
申请号:US15827539
申请日:2017-11-30
申请人: Buck Institute for Research on Aging , Mayo Foundation for Medical Education and Research , Unity Biotechnology, Inc.
发明人: Remi-Martin Laberge , Judith Campisi , Marco Demaria , Nathaniel David , Alain Philippe Vasserot , James L. Kirkland , Tamar Tchkonia , Yi Zhu , Darren J. Baker , Bennett G. Childs , Jan M. A. van Deursen
IPC分类号: A61K31/496 , A61K31/728 , A61K31/4178 , A61K9/00
CPC分类号: A61K31/496 , A61K9/0048 , A61K9/0073 , A61K31/404 , A61K31/4178 , A61K31/428 , A61K31/4375 , A61K31/495 , A61K31/5377 , A61K31/728 , A61K45/06 , A61K47/36 , A61P9/10 , A61P11/00 , A61P27/02 , C12N5/0081 , C12N2501/999 , C12N2503/02 , C12Q1/485
摘要: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
-
公开(公告)号:US20180117038A1
公开(公告)日:2018-05-03
申请号:US15827539
申请日:2017-11-30
申请人: Buck Institute for Research on Aging , Mayo Foundation for Medical Education and Research , Unity Biotechnology, Inc.
发明人: Remi-Martin Laberge , Judith Campisi , Marco Demaria , Nathaniel David , Alain Philippe Vasserot , James L. Kirkland , Tamar Tchkonia , Yi Zhu
IPC分类号: A61K31/496 , A61K31/728 , A61K31/4178
CPC分类号: A61K31/496 , A61K9/0048 , A61K9/0073 , A61K31/404 , A61K31/4178 , A61K31/428 , A61K31/4375 , A61K31/495 , A61K31/5377 , A61K31/728 , A61K45/06 , A61K47/36 , C12N5/0081 , C12N2501/999 , C12N2503/02
摘要: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
-
公开(公告)号:US10328073B2
公开(公告)日:2019-06-25
申请号:US16054667
申请日:2018-08-03
申请人: Unity Biotechnology, Inc. , Buck Institute for Research on Aging , Mayo Foundation for Medical Education and Research
发明人: Remi-Martin Laberge , Judith Campisi , Marco Demaria , Nathaniel David , Alain Philippe Vasserot , James L. Kirkland , Tamar Tchkonia , Yi Zhu , Darren J. Baker , Bennett G. Childs , Jan M. A. van Deursen
IPC分类号: A61K31/496 , A61P27/02 , A61P11/00 , A61P9/10 , A61K31/428 , A61K31/495 , A61K31/5377 , A61K31/404 , A61K31/4375 , A61K45/06 , A61K31/4178 , A61K31/728 , C12N5/00 , A61K47/36 , A61K9/00
摘要: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
-
15.
公开(公告)号:US10328058B2
公开(公告)日:2019-06-25
申请号:US15792593
申请日:2017-10-24
申请人: Mayo Foundation for Medical Education and Research , Unity Biotechnology, Inc. , Buck Institute for Research on Aging
发明人: Darren J. Baker , Marco Demaria , Albert Davalos , Bennett G. Childs , Jan M. A. van Deursen , James L. Kirkland , Tamar Tchkonia , Yi Zhu , Nathaniel David , Remi-Martin Laberge , Judith Campisi
IPC分类号: A61P9/10 , A61K31/496 , A61K31/4178 , A61K31/404 , A61K31/428 , A61K31/4375 , A61K31/5377 , A61K9/00 , A61K31/4164 , A61K45/06 , A61K47/36 , C12N5/00
摘要: Foamy macrophages with senescence markers accumulate in the subendothelial space at the onset of atherosclerosis where they drive pathology by increasing expression of key atherogenic and inflammatory cytokines and chemokines. In advanced lesions, senescent cells promote features of plaque instability, including elastic fiber degradation and fibrous cap thinning, by heightening metalloprotease production. This invention provides methods and materials for treating arthritis by removing senescent cells in or around atherosclerotic plaques, thereby stabilizing the plaques, inhibiting rupture of the plaques and pathological sequelae that manifest as coronary artery disease.
-
公开(公告)号:US10258618B2
公开(公告)日:2019-04-16
申请号:US15955542
申请日:2018-04-17
申请人: Buck Institute for Research on Aging , Unity Biotechnology, Inc. , Mayo Foundation for Medical Education and Research
发明人: Remi-Martin Laberge , Judith Campisi , Marco Demaria , Nathaniel David , Darren J. Baker , James L. Kirkland , Tamar Tchkonia , Yi Zhu , Jan M. A. van Deursen
IPC分类号: A61K9/00 , A61K31/496 , A61K31/5377 , A61P11/00 , A61K31/428 , A61K31/495 , A61K31/404 , A61K31/4375 , A61K45/06 , A61K31/4178 , A61K31/728 , C12N5/00 , A61K47/36
摘要: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
-
公开(公告)号:US20180256568A1
公开(公告)日:2018-09-13
申请号:US15950965
申请日:2018-04-11
申请人: Buck Institute for Research on Aging , Unity Biotechnology, Inc. , Mayo Foundation for Medical Education and Research , The Johns Hopkins University
发明人: Remi-Martin Laberge , Judith Campisi , Albert Davalos , Marco Demaria , Nathaniel David , Alain Philippe Vasserot , Darren J. Baker , Bennett G. Childs , James L. Kirkland , Tamar Tchkonia , Jan M.A. van Deursen , Jennifer Elisseeff , Chaekyu Kim , Okhee Jeon , Allyson K. Palmer , Yi Zhu
IPC分类号: A61K31/496 , A61K31/4375 , A61K31/5377 , A61K31/428 , A61K31/404 , A61K45/06
CPC分类号: A61K31/496 , A61K9/0048 , A61K9/0073 , A61K31/404 , A61K31/4178 , A61K31/428 , A61K31/4375 , A61K31/495 , A61K31/5377 , A61K31/728 , A61K45/06 , A61K47/36 , A61P9/10 , A61P11/00 , A61P27/02 , C12N5/0081 , C12N2501/999 , C12N2503/02 , C12Q1/485
摘要: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
-
公开(公告)号:US09980962B2
公开(公告)日:2018-05-29
申请号:US15647688
申请日:2017-07-12
申请人: Buck Institute for Research on Aging , Unity Biotechnology, Inc. , Mayo Foundation for Medical Education and Research
发明人: Remi-Martin Laberge , Judith Campisi , Marco Demaria , Nathaniel David , Darren J. Baker , James L. Kirkland , Tamar Tchkonia , Jan M. A. van Deursen , Yi Zhu
IPC分类号: A61K31/537 , A61K31/496 , A61K31/495 , A61K31/5377 , A61K31/404 , A61K31/4375 , A61K31/428 , A61K45/06 , A61K9/00
CPC分类号: A61K31/496 , A61K9/0048 , A61K9/0073 , A61K31/404 , A61K31/4178 , A61K31/428 , A61K31/4375 , A61K31/495 , A61K31/5377 , A61K31/728 , A61K45/06 , A61K47/36 , C12N5/0081 , C12N2501/999 , C12N2503/02
摘要: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
-
公开(公告)号:US09855266B2
公开(公告)日:2018-01-02
申请号:US15467129
申请日:2017-03-23
申请人: Buck Institute for Research on Aging , Unity Biotechnology, Inc. , Mayo Foundation for Medical Education and Research , The Johns Hopkins University
发明人: Remi-Martin Laberge , Judith Campisi , Albert Davalos , Marco Demaria , Nathaniel David , Alain Philippe Vasserot , James L. Kirkland , Tamar Tchkonia , Jennifer Elisseeff , Chaekyu Kim , Okhee Jeon , Yi Zhu
IPC分类号: A61K31/417 , A61K31/496 , A61K47/36 , A61K31/4178
CPC分类号: A61K31/496 , A61K9/0048 , A61K9/0073 , A61K31/404 , A61K31/4178 , A61K31/428 , A61K31/4375 , A61K31/495 , A61K31/5377 , A61K31/728 , A61K45/06 , A61K47/36 , C12N5/0081 , C12N2501/999 , C12N2503/02
摘要: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
-
公开(公告)号:US20170348307A1
公开(公告)日:2017-12-07
申请号:US15647688
申请日:2017-07-12
申请人: Buck Institute for Research on Aging , Unity Biotechnology, Inc. , Mayo Foundation for Medical Education and Research , The Johns Hopkins University
发明人: Remi-Martin Laberge , Judith Campisi , Albert Davalos , Marco Demaria , Nathaniel David , Alain Philippe Vasserot , Darren J. Baker , Bennett G. Childs , James L. Kirkland , Tamar Tchkonia , Jan M.A. van Deursen , Jennifer Elisseeff , Chaekyu Kim , Okhee Jeon , Allyson K. Palmer
IPC分类号: A61K31/496 , A61K31/5377 , A61K31/495 , A61K31/4375 , A61K31/428 , A61K45/06 , A61K31/404
CPC分类号: A61K31/496 , A61K9/0048 , A61K9/0073 , A61K31/404 , A61K31/4178 , A61K31/428 , A61K31/4375 , A61K31/495 , A61K31/5377 , A61K31/728 , A61K45/06 , A61K47/36 , C12N5/0081 , C12N2501/999 , C12N2503/02
摘要: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
-
-
-
-
-
-
-
-
-